Low-dose imatinib in the treatment of severe systemic sclerosis: A case series of six Chinese patients and literature review

Clinical Rheumatology

Volumn 31, Issue 9, 2012, Pages 1395-1400

  Guo, Li ^a   Chen, Xiao Xiang ^a   Gu, Yue Ying ^a   Zou, He Jian ^b   Ye, Shuang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Imatinib; Systemic sclerosis

Indexed keywords

ALBUMIN; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMATINIB; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ADULT; ALBUMIN BLOOD LEVEL; BRAIN HEMORRHAGE; CHINESE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG TOLERABILITY; FEMALE; FLEXION CONTRACTURE; FOLLOW UP; FRACTURE; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG FUNCTION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SYSTEMIC SCLEROSIS; TOTAL PARENTERAL NUTRITION;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASES; BENZAMIDES; CHINA; CLINICAL TRIALS AS TOPIC; FEMALE; FIBROSIS; HUMANS; LUNG; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SCLERODERMA, SYSTEMIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867889852     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2032-2     Document Type: Review

References (19)

1. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989-2003
2. Baroni SS et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354(25):2667-2676
3. Ludwicka A et al (1995) Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22(10):1876-1883
4. Li Z, Jimenez SA (2011) Protein kinase Cdelta and c-Abl kinase are required for transforming growth factor beta induction of endothelialmesenchymal transition in vitro. Arthritis Rheum 63(8):2473-2483
5. Sfikakis PP et al (2008) Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 47(5):735-737 (Pubitemid 351619226)
6. van Daele PL et al (2008) Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 58(8):2549-2552
7. Chung L et al (2009) Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 60(2):584-591
8. Tamaki Z et al (2011) Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol 22(1):94-99
9. Spiera RF et al (2011) Imatinibmesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 70(6):1003-1009
10. Pope J et al (2011) Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 63(11):3547-3551
11. Khanna D et al (2011)A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 63(11):3540-3546
12. Distler O, Distler JHW, Varga J, et al. (2010) A multi-center, openlabel, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, G.A.
13. Anonymous (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581-590
14. Clements P et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22(7):1281-1285
15. Baccarani M et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041-6051
16. Druker BJ (2003) Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother 4(6):963-971 (Pubitemid 36722486)
17. Soria A et al (2008) The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 216(2):109-117 (Pubitemid 351158574)
18. Olivieri A et al (2009) Imatinib for refractory chronic graft-versushost disease with fibrotic features. Blood 114(3):709-718
19. Chung L, Ruiz P, Wood T, et al. (2010) Evaluation of an imatinib response gene signature in patients with systemic sclerosis [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, G.A.